Author

N. Izquierdo-Useros

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Immunology· 3 Cell Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:human· 6 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:imaging· 2 Approach:microscopy & imaging analysis· 2 Organism:non-human primate· 2

Frequent Co-Authors

B. Clotet· 10 shared J. Blanco· 9 shared J. Vergara-Alert· 9 shared J. Carrillo· 8 shared J. Segales· 8 shared D. Perez-Zsolt· 7 shared V. Guallar· 7 shared B. Trinite· 6 shared

Activity by Year

2020-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersMicrobiology

B. Clotet

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

D. Raich-Regue, R. Tenorio, I. Fernandez-de-Castro, D. Perez-Zsolt, J. Munoz-Basagoiti, M. Sachse, S. Fernandez-Sanchez, M. Gallemi, P. Ortega-Gonzalez, A. Fernandez-Oliva, J. Gabaldon, E. Nunez-Delicado, J. Casas, F. Tarres, J. Vergara-Alert, , C. Risco

The paper identifies beta-cyclodextrins as effective and affordable antivirals against SARS-CoV-2 and other coronaviruses through molecular modeling and in vitro testing.

bioRxiv · Nov 16, 2022Microbiology

Actin-regulated Siglec-1 nanoclustering influences HIV-1 capture and virus-containing compartment formation in dendritic cells

M. F. Garcia-Parajo, E. Gutierrez-Martinez, S. Benet Garrab, N. Mateos, I. Erkiziac, J. A. Nieto-Garai, M. Lorizate, C. Manzo, F. Campelo, N. Izquierdo-Useros, J. Martinez-Picado

This study shows that actin-regulated Siglec-1 nanoclustering in activated dendritic cells enhances HIV-1 capture and trafficking into a single viral-containing compartment.

bioRxiv · Apr 28, 2022Cell Biology

Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis

M. Sachse, R. Tenorio, I. Fernandez de Castro, J. Munoz-Basagoiti, D. Perez-Zsolt, D. Raich-Regue, J. Rodo, A. Losada, P. Aviles, C. Cuevas, R. Paredes, J. Segales, B. Clotet, J. Vergara-Alert, N. Izquierdo-Useros, C. Risco

This study uses electron microscopy to show plitidepsin blocks SARS-CoV-2 replication organelles and virus morphogenesis.

bioRxiv · Dec 16, 2021Microbiology

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

F. Tarres-Freixas, B. Trinite, A. Pons-Grifols, M. Romero-Durana, E. Riveira-Munoz, C. Avila-Nieto, M. Perez, E. Garcia-Vidal, D. Perez-Zsolt, J. Munoz-Basagoiti, D. Raich-Regue, N. Izquierdo-Useros, I. Blanco, M. Noguera-Julian, V. Guallar, , J. Blanco

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

bioRxiv · Aug 3, 2021 · PreprintMicrobiology

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

D. Perez-Zsolt, J. Munoz Basagoiti, J. Rodo, M. Elousa, D. Raich Regue, C. Risco, M. Sachse, M. Pino, S. Gumber, M. Paiardini, J. Chojnacki, I. Erkizia, X. Muniz, E. Ballana, E. Riveira Munoz, , N. Izquierdo-Useros

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

bioRxiv · May 11, 2021 · PreprintMicrobiology

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

B. Trinite, E. Pradenas, S. Marfil, C. Rovirosa, V. Urrea, F. Tarres-Freixas, R. Ortiz, J. Vergara-Alert, J. Segales, V. Guallar, A. Lepore, N. Izquierdo-Useros, G. Trujillo, J. Trape, C. Gonzalez-Fernandez, , J. Blanco

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

bioRxiv · Mar 5, 2021Immunology

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters

M. Brustolin, J. Rodon, M. L. Rodriguez de la Concepcion, C. Avila-Nieto, G. Cantero, M. Perez, T. Nigeer, M. Noguera-Julian, V. Guallar, A. Valencia, N. Roca, N. Izquierdo-Useros, J. Blanco, B. Clotet, A. Bensaid, , J. Segales

This study shows that hamsters infected with SARS-CoV-2 are not fully protected against reinfection with both original and variant isolates, but experience reduced lung disease severity upon re-exposure.

bioRxiv · Jan 7, 2021 · PreprintPathology

Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro

J. Munoz-Basagoiti, D. Perez-Zsolt, R. Leon, V. Blanc, D. Raich-Regue, M. Cano-Sarabia, B. Trinite, E. Pradenas, J. Blanco, J. Gispert, B. Clotet, N. Izquierdo-Useros

This study shows that CPC-containing mouthwashes significantly reduce SARS-CoV-2 infectivity in vitro across variants by disrupting the viral envelope and inhibiting fusion.

bioRxiv · Dec 21, 2020Microbiology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

J. Rodon, J. Munoz-Basagoiti, D. Perez-Zsolt, M. Noguera-Julian, R. Paredes, L. Mateu, C. Quinones, I. Erkizia, I. Blanco, A. Valencia, V. Guallar, J. Carrillo, J. Blanco, J. Segales, B. Clotet, , N. Izquierdo-Useros

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology

Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

C. Verollet, M. Dupont, S. Souriant, L. Balboa, T. Phong, K. Pingris, S. Rousset, C. Cougoule, Y. Romboust, R. Poincloux, M. Ben Neji, C. Allers, D. Kaushal, M. J. Kuroda, S. Benet, , G. Lugo-Villarino

This study identifies Siglec-1 as a factor induced by TB-associated IFN-I that localizes on TNTs and promotes HIV-1 spread in macrophages.

eLife · Mar 30, 2020Peer-reviewedCell Biology